We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
+0.4%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.91B
AUM Growth
-$33.5M
(-0.48%)
Cap. Flow
-$96.8M
Cap. Flow
% of AUM
-1.4%
Top 10 Holdings %
Top 10 Hldgs %
55.6%
Holding
295
New
67
Increased
47
Reduced
98
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$81.6M |
| 2 |
NVRO
NEVRO CORP.
NVRO
|
+$68M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$61.4M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$55.5M |
| 5 |
Keurig Dr Pepper
KDP
|
+$44.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$105M |
| 2 |
Organon & Co
OGN
|
+$75.3M |
| 3 |
EXAS
Exact Sciences
EXAS
|
+$69M |
| 4 |
Biogen
BIIB
|
+$57.7M |
| 5 |
Central Garden & Pet Co Class A
CENTA
|
+$53.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 39.29% |
| 2 | Consumer Staples | 5.94% |
| 3 | Technology | 4.58% |
| 4 | Consumer Discretionary | 4.41% |
| 5 | Communication Services | 2.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Insulet
PODD
$11.8B
| $8.07M | 0.12% |
28,000
+4,000
| +17% | +$1.21M |
|
102
Kenvue
KVUE
$36.5B
| $7.93M | 0.11% |
+300,000
| New | +$7.82M |
|
103
Zura Bio
ZURA
$524M
| $7.79M | 0.11% |
+950,000
| New | +$7.63M |
|
|
MKUL
104
DELISTED
Molekule Group, Inc. Common Stock
MKUL
| $7.72M | 0.11% |
+3,299,875
| New | +$6.13M |
|
105
NVIDIA
NVDA
$5.01T
| $7.61M | 0.11% |
180,000
-120,000
| -40% | -$3.98M |
|
|
SPRB
106
Spruce Biosciences
SPRB
$119M
| $7.52M | 0.11% |
46,640
-5,733
| -11% | -$958K |
|
|
GB
107
DELISTED
Global Blue Group Holding
GB
| $7.44M | 0.11% |
+1,525,000
| New | +$8.12M |
|
108
TSMC
TSM
$2.11T
| $7.27M | 0.11% |
72,000
-20,000
| -22% | -$1.86M |
|
109
Sol-Gel Technologies
SLGL
$268M
| $6.6M | 0.1% |
220,800
-20,000
| -8% | -$700K |
|
110
M&T Bank
MTB
$36.2B
| $6.19M | 0.09% |
50,000
-50,000
| -50% | -$6.05M |
|
|
SGEN
111
DELISTED
Seagen Inc. Common Stock
SGEN
| $6.16M | 0.09% |
+32,000
| New | +$6.36M |
|
112
Marriott International
MAR
$91.5B
| $5.88M | 0.09% |
+32,000
| New | +$5.55M |
|
113
Western Alliance Bancorporation
WAL
$9.04B
| $5.84M | 0.08% |
+160,000
| New | +$5.55M |
|
114
Hilton Worldwide
HLT
$70.7B
| $5.82M | 0.08% |
+40,000
| New | +$5.7M |
|
115
X4 Pharmaceuticals
XFOR
$386M
| $5.77M | 0.08% |
+99,200
| New | +$5.1M |
|
116
Spectrum Brands
SPB
$2.04B
| $5.7M | 0.08% |
73,000
-282,000
| -79% | -$20.1M |
|
117
Nike
NKE
$63.3B
| $5.3M | 0.08% |
+48,000
| New | +$5.61M |
|
118
Advantage Solutions
ADV
$527M
| $4.94M | 0.07% |
84,440
| – | – |
|
|
RVPH
119
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
| $4.83M | 0.07% |
+41,200
| New | +$5.22M |
|
|
VSXY
120
Victoria's Secret
VSXY
$7.08B
| $4.65M | 0.07% |
266,769
+102,154
| +62% | +$2.57M |
|
|
SURF
121
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $4.25M | 0.06% |
+4,890,000
| New | +$3.49M |
|
|
BFX
122
DELISTED
BowFlex Inc.
BFX
| $4.01M | 0.06% |
+3,290,638
| New | +$4.19M |
|
123
Las Vegas Sands
LVS
$30.6B
| $3.92M | 0.06% |
+67,500
| New | +$3.99M |
|
|
CMRX
124
DELISTED
Chimerix, Inc.
CMRX
| $3.84M | 0.06% |
3,176,000
-100,000
| -3% | -$127K |
|
125
Mohawk Industries
MHK
$8.11B
| $3.71M | 0.05% |
+36,000
| New | +$3.53M |
|
Similar funds
CRC
RMDI
F
EW
O
PA
DSC
ACM
Armistice Capital's Q2 2023 Portfolio in Review
As of Q2 2023, Armistice Capital held 295 positions worth $6.91B, down 0.48% from $6.94B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Armistice Capital's Q2 2023 filing shows 67 new, 47 increased, 98 reduced and 74 closed positions. Its largest new stake was Pfizer: 2,096,000 shares worth $76.9M. The largest sale was GSK, an estimated $105M.
By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 44% a quarter earlier, followed by Consumer Staples and Technology.
- Armistice Capital's largest Q2 2023 buy was Pfizer: 2,096,000 shares worth $76.9M.
- Armistice Capital added most to Regeneron Pharmaceuticals in Q2 2023, an estimated $55.5M increase.
- Armistice Capital's biggest Q2 2023 reduction was GSK, cutting an estimated $105M.
- Armistice Capital fully exited Organon & Co in Q2 2023, selling an estimated $75.3M.
- Armistice Capital's ten largest holdings make up 56% of its $6.91B portfolio in Q2 2023.
- Armistice Capital opened 67 new positions and closed 74 in Q2 2023.
- Armistice Capital's portfolio value fell 0.48% quarter-over-quarter to $6.91B.
Based on Armistice Capital's 13F filing for Q2 2023, filed 14 Aug 2023.